Jul 2026· Journal of environmental biology· Vol 47, pp. 980-988· 0 citations
TL;DR
This comprehensive analysis indicates that dysregulation of lipid metabolism is a major pathway in MetS, with specific miRNAs functioning as critical regulatory molecules and potential therapeutic strategies targeting miRNA-mediated regulation of lipid metabolism are suggested.
Abstract
Aim: Metabolic syndrome (MetS) is a clustering of risk factors that increases susceptibility to type 2 diabetes and cardiovascular disease. This study aimed to perform a comprehensive bioinformatic analysis of genomic data to elucidate molecular pathways underlying MetS.
Methodology: GWAS data from previous MetS studies were analyzed using TargetScan, miRTarBase, Reactome Pathways, KEGG, protein–protein interaction (PPI) networks, and Gene Ontology (GO) mapping. Integration of these datasets identified key miRNAs, metabolic pathways, biological processes, and molecular activities associated with MetS.
Results: hsa-miR-126 was markedly enriched and strongly correlated with MetS. Pathway analysis highlighted cholesterol metabolism (p <0.05) and plasma lipoprotein remodeling (p <0.05) as significant contributors. GO analysis revealed triglyceride homeostasis (p <0.05) and very-low-density lipoprotein particle remodeling (p <0.05) as a key biological processes. Metabolomic analysis established strong links between triacylglycerol and glycerol metabolism. Lipid transport and metabolism emerged as central to MetS pathogenesis, with notable enrichments for high-density lipoprotein particles (p <0.05) and phosphatidylcholine-sterol O-acyltransferase activator activity (p <0.05).
Interpretation: This comprehensive analysis indicates that dysregulation of lipid metabolism is a major pathway in MetS, with specific miRNAs functioning as critical regulatory molecules. These insights suggest potential therapeutic strategies targeting miRNA-mediated regulation of lipid metabolism.
Key words: Cholesterol homeostasis, Lipid metabolism, Lipoprotein remodeling, Metabolic syndrome, miRNA regulation
The first genetically grounded mechanism for the progression of NAFLD to fibrosis is presented, which encompasssses genetic variants, dysregulated gene expression, metabolic disturbances, and the processes involved in fibrotic remodeling.
B. Peng, Meng-Ying Xu, Li Ma et al.· Journal Genetika· 0 citations
This network Mendelian randomisation study delineates protein-mediated pathways linking cluster-stratified T2D genetic predisposition to cardiovascular risk, which can inform preventive strategies by stratifying individuals based on distinct biological pathways represented by these genetic clusters.
Shuang Liao, Gabriel Chun Yin Sung, Yiwen Liang et al.· Diabetes, obesity and metabo...· 0 citations
A multi-omics model improved prediction of incident MetS over single-omics models, supporting the potential of microbiota–metabolite panels for early risk detection.
Peimeng Zhu, Jing-Feng Chen, Hang Yan et al.· Frontiers in Microbiology· 0 citations
To elucidate the molecular characteristics of synergistic interactions across the clinical stages of coronary heart disease (CHD)—specifically stable angina pectoris (SAP), unstable angina pectoris (UAP), and acute myocardial infarction (AMI)—through integrated metabolomic and proteomic analyses. Based on a cohort incl...
Xi-Lun Tan, Yuanxiaoxue Gao, Jia Wang et al.· Scientific Reports· 0 citations
Untargeted metabolomics has revealed significant systemic metabolic dysregulation in ILD and the biomarkers and “metabolic-immune-endocrine” interaction patterns identified offer potential leads for early diagnosis and targeted treatment, which require validation in larger cohorts.
Lu Liu, Xin-Yi Wang, Jinling Xiao et al.· Frontiers in Medicine· 0 citations
This study defines an RAS-SLC11A2 molecular framework linking iron metabolism dysregulation to PCOS-related cardiometabolic risk, elucidating the mechanisms connecting ovarian dysfunction, inflammation, oxidative stress and hypertension, and supports gentiopicroside as a promising therapeutic candidate.
Si-Han Zhang, Yu Xu, Tingting Cao et al.· Clinical and experimental hy...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.